NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Schmidt, Jurema ^a   Klingler, Franca Maria ^a   Proschak, Ewgenji ^a   Steinhilber, Dieter ^a   Schubert Zsilavecz, Manfred ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; DICLOFENAC; FARNESOID X-ACTIVATED RECEPTOR; HYBRID PROTEIN; IBUPROFEN; INDOMETACIN; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BINDING;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PROTEIN DOMAIN; REPORTER GENE; REPRODUCIBILITY; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL SURVIVAL; DICLOFENAC; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; IBUPROFEN; INDOMETHACIN; LIGANDS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84942921870     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14782     Document Type: Article

References (26)

1. Seol, W., Choi, H., Moore, D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9, 72-85 (1995).
2. Forman, B. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
3. Parks, D. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999).
4. Kuipers, F., Bloks, V., Groen, A. Beyond intestinal soap-bile acids in metabolic control. Nat. Rev. Endocrinol. 10, 488-498 (2014).
5. Gadaleta, R., Cariello, M., Sabbà, C., Moschetta, A. Tissue-specific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta 1851, 30-39 (2014).
6. Merk, D., Steinhilber, D., Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem. 4, 1015-1036 (2012).
7. Carotti, A. et al. Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands. Curr. Top. Med. Chem. 14, 2129-2142 (2014).
8. Lamers, C., Schubert-Zsilavecz, M., Merk, D. Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists. Curr. Top. Med. Chem. 14, 2188-2205 (2014).
9. Pellicciari, R. et al. 6?-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
10. Hirschfield, G. M. et al. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology 148, 751-761 (2014).
11. Neuschwander-Tetri, B. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965 (2014).
12. Lu, W. et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci. Rep. 5, 8114, doi: 10.1038/srep08114 (2015).
13. Merk, D., Steinhilber, D., Schubert-Zsilavecz, M. Characterizing ligands for farnesoid X receptor-available in vitro test systems for farnesoid X receptor modulator development. Expert Opin. Drug Discov. 9, 27-37 (2014).
14. Maloney, P. et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43, 2971-2974 (2000).
15. Richter, H. et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorganic Med. Chem. Lett. 21, 191-194 (2011).
16. Feng, S. et al. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorganic Med. Chem. Lett. 19, 2595-2598 (2009).
17. Merk, D. et al. Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist. J. Med. Chem. 57, 8035-8055 (2014).
18. Pantoliano, M. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429-40 (2001).
19. Niesen, F., Berglund, H., Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007).
20. Zhang, Y., Hagedorn, C., Wang, L. Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta 1812, 893-908 (2011).
21. Trauner, M., Boyer, J. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671 (2003).
22. Soroka, C., Boyer, J. Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations. Mol. Aspects Med. 37, 3-14 (2014).
23. Steri, R. et al. Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription. Future Med. Chem. 2, 575-586 (2010).
24. Steri, R., Achenbach, J., Steinhilber, D., Schubert-Zsilavecz, M., Proschak, E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem. Pharmacol. 83, 1674-1681 (2012).
25. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D., Suchy, F. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-65 (2001).
26. Seuter, S., Vaïsänen, S., Rådmark, O., Carlberg, C., Steinhilber, D. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. Biochim. Biophys. Acta 1771, 864-872 (2007).